DV
Dividend Vision

SVRA — Savara Inc

Savara Inc (SVRA)

Total return is -99.7% over the past 29.7 years, 1748.9 points behind SPY at 1649.2%. Its deepest 1-year drawdown was 32.0%.

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases, with its lead product candidate—molgramostim, an inhaled therapy—currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis. The company does not currently distribute dividends. Savara appeals to investors seeking exposure to early-stage biotech development with high risk and potential for significant upside if clinical trials succeed, rather than to those seeking current income.

SVRA key facts

Asset type
Stock
Asset class
Equity
Inception date
11/18/1996
Last close
$5.38
Market cap
$1,125,050,368
Average volume
1650100.0
Payment date
04/28/2017
Beta
0.242
Payout ratio
0.0
Forward P/E
0.4076
EPS
$-0.56